CHIARI, Rita
 Distribuzione geografica
Continente #
NA - Nord America 558
EU - Europa 385
AS - Asia 215
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1.161
Nazione #
US - Stati Uniti d'America 552
IT - Italia 133
IE - Irlanda 125
HK - Hong Kong 60
CN - Cina 58
SG - Singapore 48
VN - Vietnam 44
RO - Romania 28
UA - Ucraina 21
DE - Germania 16
RU - Federazione Russa 16
FI - Finlandia 15
FR - Francia 13
CA - Canada 5
CH - Svizzera 5
GB - Regno Unito 4
EU - Europa 2
IN - India 2
PL - Polonia 2
SE - Svezia 2
TR - Turchia 2
AT - Austria 1
BE - Belgio 1
CL - Cile 1
GR - Grecia 1
MX - Messico 1
NL - Olanda 1
RS - Serbia 1
UZ - Uzbekistan 1
Totale 1.161
Città #
Chandler 164
Dublin 125
San Mateo 66
Hong Kong 60
Perugia 56
Dong Ket 44
Singapore 34
Altamura 33
Bucharest 28
Medford 24
Princeton 24
Beijing 23
Lawrence 23
Houston 18
Andover 13
Wilmington 13
Jacksonville 10
Redmond 10
Boardman 9
San Paolo di Civitate 9
Ann Arbor 8
Des Moines 6
Saint Petersburg 6
Helsinki 5
Ottawa 5
Nanjing 4
Manassas 3
New York 3
Norwalk 3
Redwood City 3
Rome 3
Ashburn 2
Kansas City 2
Los Angeles 2
Torgiano 2
Azcapotzalco 1
Bologna 1
Brussels 1
Catania 1
Cusano Milanino 1
Dearborn 1
Den Haag 1
Esslingen am Neckar 1
Fairfield 1
Giresun 1
Izmir 1
Kiev 1
Kunming 1
Mozzo 1
Mumbai 1
Munich 1
Nagold 1
Nürnberg 1
Seattle 1
Torre Del Greco 1
Trevi 1
Totale 864
Nome #
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications 138
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 72
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 69
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 60
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 55
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 53
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer 52
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 49
Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications 49
Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol 48
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 48
EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. 47
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 45
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 45
How might treatment of ALK-positive non-small cell lung cancer change in the near future? 44
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 44
Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types 44
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 43
Osimertinib 43
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 40
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 37
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 37
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 37
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 36
Assessment of TILs, IDO-1 and PD-L1 in resected non small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. 7
Totale 1.242
Categoria #
all - tutte 5.046
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.046


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202068 1 1 3 0 7 5 6 7 8 23 7 0
2020/2021130 4 5 3 7 48 4 4 3 4 0 4 44
2021/2022251 1 47 2 4 1 2 2 66 30 21 34 41
2022/2023482 26 109 5 39 37 42 0 30 175 0 15 4
2023/2024192 11 12 9 8 0 2 55 1 8 4 43 39
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 1.242